Studies

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer

Phase III · Non-Small Cell Lung Cancer · N=450

A Phase 1 Study to Evaluate Intratumoral Doxorubicin Exposure Following Administration of Aldoxorubicin or Doxorubicin

Phase I · Soft-tissue sarcoma · N=36

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Phase II · Soft-tissue sarcoma · N=105

APROMISS: catequentinib (AL3818) in ASPS, leiomyosarcoma and synovial sarcoma

Phase III · Alveolar soft part sarcoma, leiomyosarcoma, synovial sarcoma · N=325

Catequentinib alone or with AL58805, temozolomide or CCNU (incl. STS cohorts)

Phase Ib/IIa · Soft tissue sarcoma, endometrial cancer, low-grade serous ovarian cancer, glioblastoma · N=138

AL58805 with AL8326, eribulin or fulvestrant in gynaecological cancers, STS and breast

Phase Ib/IIa · Soft tissue sarcoma, gynaecological cancers, breast cancer · N=138

ADCElerate1: ADCE-D01 (uPARAP ADC) in advanced soft tissue sarcoma

Phase I/II · Metastatic or unresectable soft tissue sarcoma · N=270

AGX101 (TM4SF1 ADC) in advanced solid tumours incl. angiosarcoma

Phase I · Advanced solid tumours incl. angiosarcoma · N=80

HH2853-G101: EZH1/2 inhibitor in r/r NHL and advanced solid tumours incl. epithelioid sarcoma

Phase I/II · Epithelioid sarcoma; relapsed/refractory non-Hodgkin lymphoma · N=254

QB46C-H07: intratumoural tigilanol tiglate in advanced soft tissue sarcoma

Phase IIa · Soft tissue sarcoma of the extremities and body wall · N=40

ATLAS: [225Ac]RTX-2358 (FAP radioligand) in relapsed or refractory soft tissue sarcoma

Phase I/II · Relapsed or refractory soft tissue sarcoma · N=48

ST-01156-101: RBM39 molecular glue degrader in advanced solid tumours incl. Ewing sarcoma

Phase I/Ib · Advanced solid tumours incl. Ewing sarcoma · N=171

Luca-1: SHY-ONC6 (19S proteasome ATPase inhibitor) in advanced solid tumours

Phase Ia/Ib · Advanced solid tumours (10 types) incl. soft tissue sarcoma · N=30

ADCLARA-01: SOT106 (LRRC15 ADC) in LRRC15-positive osteosarcoma and STS

Phase I/II · LRRC15-positive osteosarcoma and soft tissue sarcoma · N=70

STC-15 (METTL3 inhibitor) with toripalimab, and as monotherapy in selected sarcomas

Phase Ib/II · Dedifferentiated liposarcoma, uterine and non-uterine leiomyosarcoma; other advanced cancers · N=107

Afamitresgene autoleucel (MAGE-A4 TCR-T) Phase 1 dose escalation

Phase I · MAGE-A4-positive solid tumours incl. synovial sarcoma and MRCLS · N=71

SPEARHEAD-1: afamitresgene autoleucel in advanced synovial sarcoma and MRCLS

Phase II · Advanced synovial sarcoma, myxoid/round cell liposarcoma · N=52

SPEARHEAD-3: afamitresgene autoleucel paediatric basket

Phase I/II · MAGE-A4-positive synovial sarcoma, MPNST, neuroblastoma, osteosarcoma (ages 2-17) · N=20

ZL-6201-001: LRRC15 ADC in sarcoma and selected epithelial solid tumours

Phase Ia/Ib · Sarcoma and selected epithelial solid tumours · N=180